LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: American Society of Hematology
Languages: English
Types: Article
Subjects: Lymphoid Neoplasia

Classified by OpenAIRE into

mesheuropmc: hemic and lymphatic diseases, immune system diseases, neoplasms, cardiovascular diseases
Identifiers:pmc:PMC3744991
FK866 combined with bortezomib induces synergistic anti-MM cell death.Addition of low doses of NAD+-depleting agent FK866 overcomes bortezomib resistance in MM cells.

Share - Bookmark

Download from

Cite this article

Collected from